Ovarian hyperstimulation syndrome: The best approaches for prevention and treatment: A mini-review

Current Women's Health Reviews

Volumn 3, Issue 1, 2007, Pages 49-54

  Manno, Massimo ^a   Tomei, Francesco ^a   Fasciani, Alessandro ^b   Costa, Mauro ^b  

^a Pordenone Hospital   (Italy)

^b GALLIERA HOSPITAL   (Italy)

Author keywords

Cabergoline; GnRH antagonists; HCG; Metformin; OHSS; VEGF

Indexed keywords

CABERGOLINE; CHORIONIC GONADOTROPIN; CORTICOSTEROID; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HUMAN ALBUMIN; METFORMIN; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; PROGESTERONE; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE; VASCULOTROPIN;

ADULT RESPIRATORY DISTRESS SYNDROME; ANGIOGENESIS; ASCITES; BLOOD VESSEL PERMEABILITY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DEATH; DIABETES MELLITUS; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ENDOMETRIUM; FEMUR NECK FRACTURE; HEMATOCRIT; HIGH RISK POPULATION; HUMAN; INFERTILITY THERAPY; KIDNEY FAILURE; LOW DRUG DOSE; LUTEOLYSIS; OSTEOPOROSIS; OVARY FOLLICLE DEVELOPMENT; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PATHOPHYSIOLOGY; PLEURA EFFUSION; PREGNANCY RATE; PRIORITY JOURNAL; PROGESTERONE RELEASE; PROGESTERONE SYNTHESIS; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; SIDE EFFECT; STOMACH DISEASE; TERATOGENICITY; THROMBOEMBOLISM;

EID: 33847682284     PISSN: 15734048     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340407779941868     Document Type: Review

References (53)

1. Rydberg E, Pedersen-Bjergaard K. Effect of serum gonadotropin and chorionic gonadotropin on human ovary. JAMA 1943; 121: 1117-22.
2. ESHRE Ovarian Hyperstimulation syndrome (OHSS) guidelines. Delvigne A, De Sutter P, Dhont M, Gerris J, Olivennes F, Nygren KG. www.eshre.com.
3. Mc Clure N, Healy DL, Rogers PA, et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyper stimulation syndrome. Lancet 1994; 344: 235-6.
4. Wang TH, Horng SG, Chang CL, et al. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up regulation of vascular endothelial growth factor. J Clin Endocrinol Metab 2002; 87: 3300-8.
5. Papanikolau EG, Tournaye H, Verpoest W, et al. Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. Hum Reprod 2005; 20: 636-41.
6. Zimmermann RC, Xiao E, Bohlen P, Ferin M. Administration of antivascular endothelial growth factor receptor 2 antibody in the early follicular phase delays follicular selection and development in rhesus monkey. Endocrinology 2002; 143: 2496-502.
7. Fraser HM, Wilson H, Morris KD, Swanston I, Wiegand SJ. Vascular endothelial growth factor trap suppress ovarian function at all stages of the luteal phase in the macaque. J Clin Endocrinol Metab 2005; 90: 5811-8.
8. Ghosh D, Sengupta J. Target-oriented anti-implantation approaches for pregnancy interception: experiences in the rhesus monkey model. Contraception 2005; 71: 294-301.
9. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611.
10. Raziel A, Friedler S, Schachter M, Strassburger D, Mordechai E, Ron-El R. Increased early pregnancy loss in IVF patients with severe ovarian hyperstimulation syndrome. Hum Reprod 2002; 17: 107-10.
11. Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysys of preventive measures. Hum Reprod Update 2003; 3: 275-89.
12. Abdalla HI, Ah-Moye M, Brindsen P, Howe DL, Okonfua F, Craft I. The effect of the dose of HCG and the typed gonadotropins stimulation on oocytes recovery rates in an IVF program. Fertil Steril 1987; 48: 958-63.
13. International Recombinant Human Chorionic Gonadotropin Study Group. Induction of ovulation in World Health Organization group II anovulatory women undergoing follicular stimulation with recombinant human follicle-stimulating hormone: a comparison of recombinant human chorionic gonadotropins (rhCG) and urinary hCG. Fertil Steril 2001; 75: 1111-8.
14. Shaltout A, Eid M, Shohayeb A. Does triggering ovulation by 5000 IU of urinary human gonadotropins affect intracytoplasmic sperm injection (ICSI) outcome? (abstract). Hum Reprod 2006; 21 (Suppl 1): i35 O-094 (XXII Annual Meeting Eshre Prague).
15. Schmidt DW, Maier DB, Nulsen JC, Benadiva CA. Reducing the dose of human chorionic gonadotropins in high responders does not affect the outcomes of in vitro fertilization. Fertil Steril 2004; 82: 841-6.
16. The European Recombinant Human Chorionic Gonadotropin Study Group. Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment recombinant versus urinary HCG. Hum Reprod 2000; 15: 1446-51.
17. Al-Inany H, Abou-Setta A, Alboulghar M. Gonadotropin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2006; 3: CD001750.
18. Asimakopoulos B, Nikolettos N, Nehls B, Diedrich K, Al-Hasani S, Metzen E. Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures. Fertil Steril 2006 Aug 8; [Epub ahead of print].
19. Barmat LI, Chantilis SJ, Hurst BS, Dickey RP. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/ recombinant follicle-stimulating hormone rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization. Fertil Steril 2005; 83: 321-30.
20. Delvigne A, Rozenberg S. Preventive Attitude of physicians to avoid OHSS in IVF patients. Hum Reprod 2001; 12: 2491-2495.
21. Garcia-Velasco JA, Zuniga A, Pacheco A, et al. Coasting acts through down-regulation of VEGF gene expression and protein secretion. Hum Reprod 2004; 19: 1530-8.
22. The Practice Committee of the American Society for Reproductive Medicine Ovarian hyperstimulation syndrome. Fertil Steril 2004; 82 (Suppl 1): S81-6.
23. D'Angelo A, Amso N. "Coasting" (withholding gonadotropins) for preventing ovarian byperstimulation syndrome. Cochrane Database Syst Rev 2002; 3: CD002811.
24. D'Angelo A, Amso N. Embryo freezing for preventing ovarian hyperstimulation syndrome: a Cochrane review. Hum Reprod 2002; 17: 2787-94.
25. Aboulghar MA, Evers JH, Al-Inany H. Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2002; 2: CD001302.
26. Bellver J, Munoz EA, Ballesteros A, et al. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high risk IVF patients: a randomized controlled study. Hum Reprod 2002; 18: 2283-8.
27. Doldi N, Destefani A, Gessi A, Grossi D, Ferrari A. Human albumin enhances expression of vascular endothelial growth facto in cultured human luteinizing granulosa cells: importance in ovarian hyperstimulation syndrome. Hum Reprod 1999; 14: 1157-9.
28. Lainas T, Petsas G, Stavropoulou G, Alexopoulou. E, Iliadis G, Minaretzis D. Administration of methylprednisolone to prevent severe ovarian hyperstimulation syndrome in patients undergoing in vitro fertilization. Fertil Steril 2002; 78: 529-33.
29. Tan SL, Balen A, El Hussein E, Campbell S, Jacobs HS. The administration of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in in vitro fertilization: a prospective randomized study. Fertil Steril 1992; 58: 378-82.
30. Iwai A, Fujii Y, Kawakami S, et al. Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids. Mol Cell Endocrinol 2004; 226: 11-7.
31. Keay SD, Lenton EA, Cooke ID, Hull MGR, Jenkins JM. Low-dose dexamethasone augments the ovarian response to exogenous gonadothropins leading to a reduction in cycle cancellation rate in a standard IVF programme. Hum Reprod 2001; 16: 1861-5.
32. Hohmann FP, Macklon NS, Fauser BCJM. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J Clin Endocrinol Metab 2003; 88: 166-73.
33. Humaidan P, Ejdrup Bredkjaer H, Bungum L, et al. GnRH agonist (buserelin) or HCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2005; 20: 1213-20.
34. Kolbianakis EM, Schulze-Mosgau A, Schrore A, et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 2005; 10: 2887-92.
35. Griesinger G, Diedrich K, Devroey P, Kolbianakis EM. GnRH agonist for triggering final oocytes maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 2006; 12(2): 159-68.
36. Ricoiarelli E, Acevedo-Martin B, Gomez-Palomares JL, Pareja A, Hernandez ER. Triggering ovulation with GnRH agonists does not compromise embryo implantability. Hum Reprod 2006; 21 (Suppl 1) i35 O-093 (XXII Annual Meeting Eshre Prague).
37. Tesarik J, Hazout A, Mendoza C. Enhancement of embryo developmental potential by a suingle administration of GnRH agonist at the time of implantation. Hum Reprod 2004; 19: 1176-80.
38. Filicori M, Fazleabas AT, Huhtaniemi I, et al. Nonvel concepts of human chorionic gonadotropins: reproductive system interactions and potential in the management of infertility. Fertil Steril 2005; 84: 275-84.
39. Pirard C, Donnez J, Loumaye E. GnRH agonists luteal phase support in assisted reproduction technique cycles: results of a pilot study. Hum Reprod 2006; 21: 1894-900.
40. Papanikolau EG, Pozzobon C, Kolbianakis EM, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropins-releasing hormone antagonist in vitro fertilization. Fertil Steril 2006; 85: 112-20.
41. Nakhuda GS, Chu MC, Wang JG, Sauer MV, Lobo RA. Elevated serum mullerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. Fertil Steril 2006; 85: 1541-3.
42. Braat DDM, Bernardus RE, Mooij T, Schutte JM, van Leeuwen. Mortality after IVF. Hum Reprod 2006; 21 (Suppl 1): i97 O-251 (XXII Annual Meeting Eshre Prague).
43. Costello MF, Chapman M, Conway U. A systematic review and meta-analysis of randomised controlled trials on metformin co-administration during gonadotropin ovulation induction or IVF in women with polycystic ovary syndrome. Hum Reprod 2006; 21: 1387-99.
44. Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS. Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod 2005; 20: 1820-6.
45. Tang T, Glanville J, Orsi N, Barth JH, Balen AH. The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod 2006; 21: 1416-25.
46. Khattab S, Aboul Fotouh I, Abdel Mohesn I, Metwally M, Moaz M. Use of metformin for prevention of ovarian hyperstimulation syndrome: a novel approach. Reprod Biomed Online 2006; 13: 194-7.
47. Basu S, Nagy JA, Pal S, et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 2001; 7: 569-74.
48. Sulkowska M, Famulski W, Wicewicz A, et al. Levels of VE-cadherin increase independently of VEGF in preoperative sera of patients with colorectal cancer. Tumori 2006; 92: 67-71.
49. Villasante A, Pacheco A, Ruiz A, Pellicer A, Garcia-Velasco JA. Vascular endothelial cadherin regulates vascular permeabilità: Implications for ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 2006 Oct 10; [Epub ahead of print].
50. Ricci E, Parazzini F, Motta T, et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 2002; 16: 791-3.
51. Manno M, Tomei F, Marchesan E, Adamo V. Cabergoline: a safe, easy, cheap and effective drug for prevention/treatment of ovarian hyperstimulation syndrome. Eur J Obset Gynecol Reprod Biol 2005; 122: 126-30.
52. Manno M. Can we eliminate severe ovarian hyperstimulation syndrome ? Comment I. Hum Reprod 2005; 8: 2368-9.
53. Alvarez C, Bosch E, Melo MAB, et al. The dopamine agonist Cabergoline prevents moderate-severe early ovarian hyperstimulation sindrome (OHSS) in high risk ART patients. Hum Reprod 2006; 21 (suppl 1): i96 O-249 (XXII Annual Meeting Eshre Prague).